http://www.igenericdrugs.com Review Rating: 100 out of 100 based on 571 reviews. 571 stars
Generic drugs
List of interchangeable brand and generic drugs
compare generic drug prices
 

Bromegon

Choose a suitable interchangeable generic or brand drug, if you could not find the prescribed medicine.
We do not sell drugs. This site contains prices only for information purposes to help you buy drugs cheaply.
You should consult a doctor about the dosage before using this medicine!

DRUG NAME:     

 

Bromegon uses and description

Sort by popularity
Bromegon - The Cycloset brand of Bromegon is used together with diet and exercise to treat type 2 (non-insulin dependent) diabetes. Cycloset is not for treating type 1 diabetes.

The Parlodel brand of Bromegon is used to treat certain conditions caused by a hormone imbalance in which there is too much prolactin in the blood (hyperprolactinemia). Symptoms include lack of sexual development in adolescents. Women may have missed menstrual periods, loss of interest in sex, hot flashes, infertility, or unexpected breast milk production and leakage from the nipples. Men may have enlarged breasts, decreased libido, decreased facial or body hair, and loss of muscle. Parlodel is also used to treat these disorders when they are caused by brain tumors that can produce prolactin.

Parlodel is sometimes used together with surgery or radiation in treating acromegaly, a condition caused by a pituitary gland tumor that produces too much growth hormone.

Parlodel is also used to treat symptoms of Parkinson's disease, such as stiffness, tremors, muscle spasms, and poor muscle control.

Bromegon may also be used for purposes not listed in this medication guide.

Bromegon stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily consists of D1 and D5 subreceptors, which are associated with dyskinesias. The dopaminergic D2 receptor subfamily consists of D2, D3 and D4 subreceptors, which are associated with improvement of symptoms of movement disorders. Thus, agonist activity specific for D2 subfamily receptors, primarily D2 and D3 receptor subtypes, are the primary targets of dopaminergic antiparkinsonian agents. It is thought that postsynaptic D2 stimulation is primarily responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D2 stimulation confers neuroprotective effects. This semisynthetic ergot derivative exhibits potent agonist activity on dopamine D2-receptors. It also exhibits agonist activity (in order of decreasing binding affinity) on 5-hydroxytryptamine (5-HT)1D, dopamine D3, 5-HT1A, 5-HT2A, 5-HT1B, and 5-HT2C receptors, antagonist activity on α2A-adrenergic, α2C, α2B, and dopamine D1 receptors, partial agonist activity at receptor 5-HT2B, and inactivates dopamine D4 and 5-HT7 receptors. Parkinsonian Syndrome manifests when approximately 80% of dopaminergic activity in the nigrostriatal pathway of the brain is lost. As this striatum is involved in modulating the intensity of coordinated muscle activity (e.g. movement, balance, walking), loss of activity may result in dystonia (acute muscle contraction), Parkinsonism (including symptoms of bradykinesia, tremor, rigidity, and flattened affect), akathesia (inner restlessness), tardive dyskinesia (involuntary muscle movements usually associated with long-term loss of dopaminergic activity), and neuroleptic malignant syndrome, which manifests when complete blockage of nigrostriatal dopamine occurs. High dopaminergic activity in the mesolimbic pathway of the brain causes hallucinations and delusions; these side effects of dopamine agonists are manifestations seen in patients with schizophrenia who have overractivity in this area of the brain. The hallucinogenic side effects of dopamine agonists may also be due to 5-HT2A agonism. The tuberoinfundibular pathway of the brain originates in the hypothalamus and terminates in the pituitary gland. In this pathway, dopamine inhibits lactotrophs in anterior pituitary from secreting prolactin. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion making Bromegon an effective agent for treating disorders associated with hypersecretion of prolactin. Pulmonary fibrosis may be associated bromocriptine’s agonist activity at 5-HT1B and 5-HT2B receptors.

Bromegon is used alone or together with other medicines to treat Parkinson's Disease. It is used to improve the medicinal effect of other Parkinson's Disease medicines such as levodopa. Bromegon cannot cure Parkinson's Disease but it can improve the quality of life for people who have the disease. Bromegon may sometimes be used to treat other conditions.

Oral Parkinson's disease

Adult: As adjunct to levodopa: 1st wk: Initially, 1-1.25 mg at night; 2nd wk: 2-2.5 mg at night; 3rd wk: 2.5 mg bid; 4th wk: 2.5 mg tid, then increased by 2.5 mg every 3-14 days as required.

Maintenance: 10-40 mg daily. Oral Hypogonadism

Adult: 1-1.25 mg at bedtime increased to 2-2.5 mg at bedtime after 2-3 days and subsequently increased by 1 mg at 2-3 days intervals, up to 2.5 mg bid or more if necessary. Max: 30 mg daily. Oral Galactorrhoea

Adult: 1-1.25 mg at bedtime increased to 2-2.5 mg at bedtime after 2-3 days and subsequently increased by 1 mg at 2-3 days intervals, up to 2.5 mg bid or more if necessary. Max: 30 mg daily. Oral Infertility

Adult: 1-1.25 mg at bedtime increased to 2-2.5 mg at bedtime after 2-3 days and subsequently increased by 1 mg at 2-3 days intervals, up to 2.5 mg bid or more if necessary. Max: 30 mg daily. Oral Adjunct to surgery and radiotherapy in patients with acromegaly

Adult: Initially, 2.5 mg bid, may increase further by 2.5 mg every 2-3 days, if necessary up to 5 mg every 6 hr depending on response. Oral Suppression of lactation

Adult: 2.5 mg daily for 2-3 days, increased gradually to 2.5 mg bid for 14 days. Oral Prophylaxis of puerperal lactation

Adult: 2.5 mg on the day of delivery followed by 2.5 mg bid for 14 days. Oral Cyclical benign breast and menstrual disorders

Adult: 2.5 mg bid.

Oral Parkinson's disease

Adult: As adjunct to levodopa: 1st wk: Initially, 1-1.25 mg at night; 2nd wk: 2-2.5 mg at night; 3rd wk: 2.5 mg bid; 4th wk: 2.5 mg tid, then increased by 2.5 mg every 3-14 days as required.

Maintenance: 10-40 mg daily. Oral Hypogonadism

Adult: 1-1.25 mg at bedtime increased to 2-2.5 mg at bedtime after 2-3 days and subsequently increased by 1 mg at 2-3 days intervals, up to 2.5 mg bid or more if necessary. Max: 30 mg daily. Oral Galactorrhea

Adult: 1-1.25 mg at bedtime increased to 2-2.5 mg at bedtime after 2-3 days and subsequently increased by 1 mg at 2-3 days intervals, up to 2.5 mg bid or more if necessary. Max: 30 mg daily. Oral Infertility

Adult: 1-1.25 mg at bedtime increased to 2-2.5 mg at bedtime after 2-3 days and subsequently increased by 1 mg at 2-3 days intervals, up to 2.5 mg bid or more if necessary. Max: 30 mg daily. Oral Adjunct to surgery and radiotherapy in patients with acromegaly

Adult: Initially, 2.5 mg bid, may increase further by 2.5 mg every 2-3 days, if necessary up to 5 mg every 6 hr depending on response. Oral Suppression of lactation

Adult: 2.5 mg daily for 2-3 days, increased gradually to 2.5 mg bid for 14 days. Oral Prevention of puerperal lactation

Adult: 2.5 mg on the day of delivery followed by 2.5 mg bid for 14 days. Oral Cyclical benign breast and menstrual disorders

Adult: 2.5 mg bid.

Indications:

Adult: PO Parkinson's disease As adjunct to levodopa: 1st wk: 1-1.25 mg at night, 2nd wk: 2-2.5 mg at night; 3rd wk: 2.5 mg twice daily; 4th wk: 2.5 mg 3 times/day, then increase as needed.

Maintenance: 10-40 mg/day. Galactorrhoea ; Hypogonadism; Infertility 1-1.25 mg at bedtime, increase gradually. Max: 30 mg/day. Adjunct to surgery and radiotherapy in patients w/ acromegaly Initial: 2.5 mg twice daily, increase slowly, up to 5 mg 6 hrly if needed. Lactation suppression 2.5 mg/day for 2-3 days, up to 2.5 mg twice daily for 14 days. Prevention of puerperal lactation 2.5 mg on the day of delivery, then 2.5 mg twice daily for 14 days. Cyclical benign breast and menstrual disorders 2.5 mg twice daily.

Bromegon (bromocriptine mesylate) is indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Parlodel treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of Parlodel therapy may be used to reduce the tumor mass prior to surgery. AcromegalyParlodel therapy is indicated in the treatment of acromegaly. Parlodel therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with Parlodel offers potential benefit before the effects of irradiation are manifested. Parkinson’s DiseaseParlodel SnapTabs® or capsules are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson’s disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), Parlodel therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing "end of dose failure’’ on levodopa therapy. Parlodel therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function ("on-off’’ phenomenon). Continued efficacy of Parlodel therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson’s disease with Parlodel. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in Parlodel-treated patients than in levodopa/carbidopa-treated patients. Patients unresponsive to levodopa are poor candidates for Parlodel therapy.

Active ingredients: Bromocriptine
Unit description, dosagePrice, USD

List of bromegon brand and generic drugs

Bromed
Tablet; Oral; Bromocriptine Mesylate 2.5 mg
Bromergon (Bangladesh, Croatia (Hrvatska), Poland, Slovenia)
Tablet; Oral; Bromocriptine 2.5 mg
Bromergon 2.5 mg x 30's
Bromicon (Pakistan)
Bromidine (South Korea)
Bromo-Kin (France)
Capsule; Oral; Bromocriptine Mesylate 10 mg
Capsule; Oral; Bromocriptine Mesylate 5 mg
Tablet; Oral; Bromocriptine Mesylate 2.5 mg
Bromo-Kin Inhibition de la Lactation
Tablet; Oral; Bromocriptine Mesylate 2.5 mg
Bromocorn (Poland)
Bromocrel
Tablet; Oral; Bromocriptine Mesylate 2.5 mg
Bromocriptin
Tablet; Oral; Bromocriptine Mesylate 2.5 mg
Bromocriptin 2.5
Bromocriptin AbZ (Germany)
Bromocriptin beta (Germany)
Bromocriptin Hexal (Germany)
Bromocriptin Richter (Estonia, Georgia, Hong Kong, Hungary, Latvia, Lithuania, Russian Federation)
Bromocriptin-CT (Germany)
Bromocriptin-ratiopharm (Germany)
Bromocriptina Dorom (Italy, Romania)
Bromocriptina Generis (Portugal)
Bromocriptine (Japan)
Capsule; Oral; Bromocriptine Mesylate 5 mg
Tablet; Oral; Bromocriptine Mesylate 2.5 mg
Bromocriptine mesylate powd$ 384.03
Parlodel 5 mg capsule$ 9.25
Parlodel 2.5 mg tablet$ 5.64
Bromocriptine Mesylate 5 mg capsule$ 5.21
Bromocriptine Mesylate 2.5 mg tablet$ 2.28
Bromocriptine 2.5 mg tablet$ 2.18
Apo-Bromocriptine 5 mg Capsule$ 1.02
Pms-Bromocriptine 5 mg Capsule$ 1.02
Apo-Bromocriptine 2.5 mg Tablet$ 0.57
Pms-Bromocriptine 2.5 mg Tablet$ 0.57
Bromocriptine NIHFI (Bulgaria)
Bromocriptine Poli (Lithuania)
Bromocriptine Sopharma (Bulgaria)
Bromocriptine-BC
Tablet; Oral; Bromocriptine Mesylate 2.5 mg
Tablet; Oral; Bromocriptine Mesylate 5 mg
Bromocriptine-Richter (Singapore)
Bromocriptine-Richter 2.5 mg x 30's$ 24.00
Bromodel (Bangladesh)
Bromodel 10
Bromodel 2.5

Show all Bromegon generic names
 
Privacy Policy
© 2003 - 2014 igenericdrugs.com All Rights Reserved
 
Disclamer